Gene-based bin analysis of genome-wide association studies
- Nicolas Omont^{1, 2},
- Karl Forner^{1},
- Marc Lamarine^{1},
- Gwendal Martin^{1},
- François Képès^{2} and
- Jérôme Wojcik^{1}Email author
https://doi.org/10.1186/1753-6561-2-s4-s6
© Omont et al; licensee BioMed Central Ltd. 2008
Published: 17 December 2008
Abstract
Background
With the improvement of genotyping technologies and the exponentially growing number of available markers, case-control genome-wide association studies promise to be a key tool for investigation of complex diseases. However new analytical methods have to be developed to face the problems induced by this data scale-up, such as statistical multiple testing, data quality control and computational tractability.
Results
We present a novel method to analyze genome-wide association studies results. The algorithm is based on a Bayesian model that integrates genotyping errors and genomic structure dependencies. p-values are assigned to genomic regions termed bins, which are defined from a gene-biased partitioning of the genome, and the false-discovery rate is estimated. We have applied this algorithm to data coming from three genome-wide association studies of Multiple Sclerosis.
Conclusion
The method practically overcomes the scale-up problems and permits to identify new putative regions statistically associated with the disease.
Background
The last years have shown a tremendous increase in the number of markers available for association studies. Previous studies were dealing either with the whole genome at a very low resolution (for instance 5 264 microsatellites in [1]) or with a carefully chosen region of few millions of base pairs [2, 3]. Recent technologies allow the genome-wide genotyping of hundred of thousands SNPs [4]. This has arisen the need of new methodological developments to overcome different issues, such as the multiple-testing problem, gene biases, data quality analysis and the computational tractability.
Firstly, the multiple testing problem seems to cause association studies ability to detect associations to decrease as the number of markers increases. The classical analysis strategy, based on an association test for each marker [5], encounters increasing difficulties as more than one million of markers are available: Increasing the number of markers prevents from the detection of the mild genetic effects expected in complex diseases, as only strong effects emerges from the huge noise generated by the increased quantity of data.
Methods like False Discovery Rate (FDR) [6] computation allow to control the error rigorously, but do not increase the statistical power. Better strategies based on haplotype blocks are being developed, the first step being gathering such block data (see the HapMap project, [7]). The gain of such strategies is two-folded: (i) the number of tests is independent of the number of markers (ii) the statistical power may be increased if markers of the same haplotype block are not fully correlated.
Secondly, a genetic association of a given SNP is a statistical feature and does not explain by itself a phenotype. To biologically interpret an associated marker, its haplotype block should first be delimited. Then, the association can be refined by fine-scale genotyping technologies or ideally by full resequencing. This eventually allows to identify functional mutations. Most of the time, these mutations impact relatively close genes. This is a first argument to bias association analysis towards genes. Moreover, even if haplotype blocks are unreachable, DNA might be cut into distinct regions (called bins) on another basis, so as to limit the multiple-testing problem and make it independent of the number of markers. Combining these two arguments leads to choose one bin for each gene, and to create "desert" bins in large unannotated regions. It allows to associate a list of genes with a test, which simplifies the analysis of results. The drawbacks are (i) that it makes more difficult the study of these "deserts", however the goal is here to maximize, not the chance of finding an association, but the chance of elucidating a mechanism of a complex disease given the current knowledge (ii) that a bin might contain several haplotype blocks, resulting in a dilution of the association signal if only one block is associated. Reciprocally, neighbor bins are not independent because they may share a haplotype block. However, with the classical strategy, correlated neighbor SNPs would also be tested separately.
Thirdly, genome-wide genotyping data are obtained by high-throughput experiments which encompass limitations requiring careful statistical methodology. Especially, with Affy. technology, the trade-off between the call rate (i.e. errors detected by the genotyping process and resulting in missing genotypes in the data set) and the error rate (i.e. errors left in the data) is difficult to adjust. Obtaining unbiased statistical results is then conditioned to good pre-processing filters. Indeed spurious markers must be eliminated and missing data correctly managed.
In addition, for most of SNPs used in this study, some genotypes are held by less than few percents of patients, which, given the usual collection size of a few hundreds, (i) is not enough for good asymptotic approximations and (ii) should be considered with care given possible high error rate.
Finally, whatever algorithmic solution is developed, because the number of markers available will probably quickly reach a few millions, creating a scalability problem, it has to be linear in the number of markers.
In this paper we present a novel Bayesian algorithm developed to easily analyze genome-wide association studies. This algorithm is based on a gene-based partitioning of DNA into regions, called bins. A p-value of association is computed for each bin. The model takes into account genotyping errors and missing data and tries to detect simple differences in the haplotype block structure between cases and controls. The study of different collections is allowed. The multiple testing problem is addressed by estimation of FDR. The method has been applied to analyze the results of three genome-wide case-control association studies of the complex disease Multiple Sclerosis (MS). It identifies putatively associated bins, containing genes previously described to be linked to MS (see [8] for review) as well as new candidate genes.
Materials
Genome-wide association multiple sclerosis collections.
Coll. | Origin | #Cases | #Controls | %Females |
---|---|---|---|---|
A | French | 314 | 352 | 69 |
B | Swedish | 279 | 301 | 71 |
C | American | 289 | 289 | 85 |
Methods
Notations
Data preprocessing
Therefore, the following pre-processing filters are applied: SNPs are discarded (i) if the number of missing genotypes is higher than 5% because the genotyping process quality was low for this SNP, (ii) if the minimum allele frequency in controls MAF = min(P(a), P(A)) is lower than 1%, because the SNP holds no information, or (iii) if the probability that the SNP follows the Hardy-Weinberg equilibrium in controls is lower than 0.02.
Bin definition
Assessing bin association
General model, hypotheses and statistics
On the contrary, due to the experimental design, estimations of $P(\mathcal{S},{\mathcal{V}}_{m})$ are impossible.
p-value estimation and FDR
In this article, estimation of p-values is based on permutations: possible outcomes are obtained through patient phenotype permutations σ and σ_{0} is the identity permutation. The probability of each permutation is uniform. The denominator of equation (8) is constant with respect to such permutations, therefore it is omitted. Sampling this space is possible: random permutations of the phenotypes are drawn and used to compute a LR. This is a Monte-Carlo procedure, for which we propose an optimized implementation that guarantees the precision required for FDR estimation:
θ and γ/δ control the quality of the method: θ is an upper bound of the threshold that is expected to be used to select bins. γ/δ controls the error due to the randomness of the process: Assuming that two consecutive p-values π_{b1 }<π_{b2 }≈ θ are sufficiently spaced (probability p_{ s }= e^{-δ}), ${\widehat{\pi}}_{b1}<{\widehat{\pi}}_{b2}$ with a confidence c = cdf($\mathcal{N}$(0, 1), γ) (standard normal cumulative distribution function). In this article, B = 11 264, θ = 0.001, δ = 1 and γ = $\sqrt{2}$ thus N_{ b }= 507 003, p_{ s }= 0.37 and c = 0.92.
The numerator is an estimation of the expectation of the number of false-positive with π_{ b }≤ θ. $\widehat{{\Pi}_{0}}$ is an estimation of the proportion of bins under the null hypothesis. Given that it is expected to be very high in current study, it is (conservatively) fixed at its upper bound: $\widehat{{\Pi}_{0}}$ = 1. The denominator is the number of tests with p-values below. The ratio is therefore an estimation of the proportion of false negatives in the set of bins with a p-value below θ. Because we want to analyze thoroughly the FDR for around the 10 bins with the lowest p-values, the FDR is not controlled at a specified threshold as in [6] but only estimated.
This estimation relies on two main hypothesis: (i) tests are independent or positively correlated [11], (ii) p-values are continuously and uniformly distributed in [0, 1]. Assuming that sharing of haplotype block by neighbor bins is the only source of correlation between tests, the positive correlation seems reasonable. Indeed, if the p-value of a not associated bin decreases, the p-values of bins sharing the same haplotype block are more than likely to decrease too. The uniform distribution is less obvious, because the number of possible contingency tables is finite so that even the null distribution is not uniform. However, the sample size is one to two order of magnitude higher than in other applications of FDR to discrete data in which the problem is acute [12].
Model of linkage disequilibrium and error
Finally, this assumptions also allow to obtain correct estimations because corresponding contingency tables are sufficiently filled. They implies that contingency tables are computed for 2 SNPs (#(${\mathcal{G}}_{b}^{j}$) = 3), the phenotype (#($\mathcal{S}$) = 2) and the co-variables together. The gender co-variable is not be used. It requires the hypothesis that the SNP distribution is independent from it. The only co-variable is the study patients belong to (Table 1, #(${\mathcal{V}}_{2}$) = 3). As collection sizes for a given study are around 600, the average number of patients in each cell of contingency tables is then $\overline{n}$ = 33.
Where n_{∅} is the number of patients with either ${\mathcal{O}}_{b}^{j}$ or ${\mathcal{O}}_{b}^{j-1}$ missing and and m is the number of cells. To obtain more regular estimates, a constant is added to all cell counts. It is a Dirichlet prior on parameters. This constant is chosen to be C = α_{0}$\overline{n}$, where α_{0} is the chosen error rate and $\overline{n}$ is the mean number of individuals per cell. This constant means that uncertainty on low cell counts is high, not only because of randomness, but also because of genotyping errors.
The missing rate β is estimated for each marker through the resolution of the non-linear system drawn from the preceding model. The maximum error rate α_{0} is estimated during external comparison of Affy. technology and other technologies. In this study, the error rate is chosen to be α_{0} = 0.05. The error rate is α = min(α_{0}, P(${\mathcal{O}}_{b}^{j}$ = Aa)/(1 - P (${\mathcal{O}}_{b}^{j}$ = ∅))) in order that the system always have a solution for β.
Likelihood computation
This equation considers information coming from two neighbor markers together. Compared to the full model, information flow is limited to pair of markers. The likelihood could be falsely increased in this extreme situation: suppose that a missing genotype is inferred aa from its left neighbor and AA from its right neighbor, the merging of this two inferences would results in a contradiction and thus a low resulting likelihood. On the contrary, the approximated likelihood does not detect this contradiction and is falsely increased. This likelihood is named thereafter "two-marker" likelihood.
Results
The method has been applied to each of the three collections A, B, C (Table 1) as well as to the three collections at once (ABC), considering the collection of origins as a co-variable. The overall computation time is about 10 days on a single processor.
The pre-processing filters discard around 20% of SNP: for collection A (resp. B and C), out of 112 463 SNP, 84 430 (resp. 93 548 and 86 652) SNP remains. If all SNP satisfied the Hardy-Weinberg equilibrium, 2 249 SNP are expected to be discarded. 9 422 were for collection A. It can be explained (i) by artifacts of DM calling algorithm which has a higher error rate on heterozygotic genotypes (ii) by deviations from the assumptions underlying this theoretical equilibrium. The bin partioning algorithm divides the genome into 19 556 gene bins and 1 993 desert bins. Out of these 21 549 bins, only 11 264 (52%) contain one SNP or more after pre-processing in at least one collection and are considered for further analysis. Before pre-processing, out of 12 512 SNP with one bin or more, 2 781 have only one SNP, and 2 188 bins 10 SNP or more. The maximum is 210.
Associated bins at FDR 5% threshold (top), at FDR 50% threshold before (middle) and after exclusion of MHC region bins (bottom). A, B, C, ABC: collection designs, L_{2}: two-marker likelihood, L_{3}: naive likelihood.
FDR 5% with MHC | L _{3} | L _{2} |
---|---|---|
A | 3 | 2 |
B | 3 | 6 |
C | 2 | 2 |
ABC | 4 | 6 |
FDR 50% with MHC | L _{3} | L _{2} |
A | 6 | 6 |
B | 14 | 7 |
C | 6 | 28 |
ABC | 20 | 33 |
FDR 50% w/o MHC | L _{3} | L _{2} |
A | 2 | 0 |
B | 1 | 1 |
C | 0 | 0 |
ABC | 8 | 10 |
Discussion
We have developed a new method to practically analyze genome-wide association studies data. Our algorithm is based on a bin partitioning of the genome, takes advantage of studying several collections simultaneously, takes into account genotyping errors and local genomic structure (LD), and handles the multiple testing problem through FDR estimation while staying computationally tractable. The method has been applied to analyze three association studies in Multiple Sclerosis.
The FDR threshold is chosen according to the desired application. To conduct expensive further experiments with putatively associated genes, a very low rate of false-positives is required. A FDR threshold of 5% seems reasonable. On the contrary, if one wants to minimize the false-negative rate, a FDR of 50% is acceptable.
Applying the method to experimental genome-wide association data on three collections permits (i) to assess the algorithm and evaluate the different parameters and design and (ii) to identify genes potentially associated to Multiple Sclerosis. We have evidenced that the three collection design outperforms the one-study design in terms of expected number of true-positives, despite differences between the studied collections, especially on the severity of the disease. Furthermore, with this three collection design, the two-marker likelihood L_{2} seems to be more efficient thanks to the additional information used. With this configuration, a FDR threshold of 5% gives 6 associated bins. Four of them are located in the MHC region, known to be linked to Multiple Sclerosis [14]. It is a validation of the method. The two others are bins containing olfactory receptor genes OR2T2 and OR4A47. The biological meaning of such association is unclear but the extended MHC regions contain many other olfactory genes [14] and olfactory dysfunction has already been reported in Multiple Sclerosis [15]. At FDR threshold of 50% and after exclusion of bins from MHC, the method selects ten bins. They open the perspective of insights to explain Multiple Sclerosis.
Declarations
Acknowledgements
We are grateful to the Serono Genetics Institute banking, genotyping and genetic analysis team for producing high-quality data. The work has been significantly made easier by the Serono Genetics Institute Research Knowledge Management team and we acknowledge them particularly. We also thank Pierre-Yves Bourguignon for the idea of the hidden Markov chain and Jean Duchon for the distribution of the distance between two p-values. This article has also been greatly improved thanks to the comments of many reviewers.
This article has been published as part of BMC Proceedings Volume 2 Supplement 4, 2008: Selected Proceedings of Machine Learning in Systems Biology: MLSB 2007. The full contents of the supplement are available online at http://www.biomedcentral.com/1753-6561/2?issue=S4.
Authors’ Affiliations
References
- Dib C, Fauré S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J, Weissenbach J: A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 1996, 380 (6570): 152-4. 10.1038/380152a0.View ArticlePubMedGoogle Scholar
- Cardon LR, Bell JI: Association study designs for complex diseases. Nature reviews Genetics. 2001, 2 (2): 91-99. 10.1038/35052543.View ArticlePubMedGoogle Scholar
- Lewis CM: Genetic association studies: design, analysis and interpretation. Briefings in bioinformatics. 2002, 3 (2): 146-153. 10.1093/bib/3.2.146.View ArticlePubMedGoogle Scholar
- Kennedy GC, Matsuzaki H, Dong S, min Liu W, Huang J, Liu G, Su X, Cao M, Chen W, Zhang J, Liu W, Yang G, Di X, Ryder T, He Z, Surti U, Phillips MS, Boyce-Jacino MT, Fodor SPA, Jones KW: Large-scale genotyping of complex DNA. Nature biotechnology. 2003, 21 (10): 1233-7. 10.1038/nbt869.View ArticlePubMedGoogle Scholar
- Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J: Complement factor H polymorphism in age-related macular degeneration. Science. 2005, 308 (5720): 385-9. 10.1126/science.1109557.PubMed CentralView ArticlePubMedGoogle Scholar
- Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B. 1995, 57 (1): 289-300.Google Scholar
- International HapMap Consortium T: A haplotype map of the human genome. Nature. 2005, 437 (7063): 1299-320. 10.1038/nature04226.View ArticleGoogle Scholar
- Dyment DA, Ebers GC, Sadovnick AD: Genetics of multiple sclerosis. Lancet neurology. 2004, 3 (2): 104-110. 10.1016/S1474-4422(03)00663-X.View ArticlePubMedGoogle Scholar
- Birney E, Andrews D, Caccamo M, Chen Y, Clarke L, Coates G, Cox T, Cunningham F, Curwen V, Cutts T, Down T, Durbin R, Fernandez-Suarez XM, Flicek P, Gräf S, Hammond M, Herrero J, Howe K, Iyer V, Jekosch K, Kähäri A, Kasprzyk A, Keefe D, Kokocinski F, Kulesha E, London D, Longden I, Melsopp C, Meidl P, Overduin B, Parker A, Proctor G, Prlic A, Rae M, Rios D, Redmond S, Schuster M, Sealy I, Searle S, Severin J, Slater G, Smedley D, Smith J, Stabenau A, Stalker J, Trevanion S, Ureta-Vidal A, Vogel J, White S, Woodwark C, Hubbard TJP: Ensembl 2006. Nucleic Acids Research. 2006, D556-D561. 10.1093/nar/gkj133. 34 DatabaseGoogle Scholar
- Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100 (16): 9440-5. 10.1073/pnas.1530509100.PubMed CentralView ArticlePubMedGoogle Scholar
- Benjamini Y, Yekutieli D: The control of the false discovery rate in multiple testing under dependency. Annals of Statistics. 2001, 29 (4): 1165-1188. 10.1214/aos/1013699998.View ArticleGoogle Scholar
- Pounds S, Cheng C: Improving false discovery rate estimation. Bioinformatics. 2004, 20 (11): 1737-45. 10.1093/bioinformatics/bth160.View ArticlePubMedGoogle Scholar
- Pounds SB: Estimation and control of multiple testing error rates for microarray studies. Briefings in bioinformatics. 2006, 7: 25-36. 10.1093/bib/bbk002.View ArticlePubMedGoogle Scholar
- Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC, Wright MW, Wain HM, Trowsdale J, Ziegler A, Beck S: Gene map of the extended human MHC. Nature reviews Genetics. 2004, 5 (12): 889-899. 10.1038/nrg1489.View ArticlePubMedGoogle Scholar
- Zivadinov R, Zorzon M, Bragadin LM, Pagliaro G, Cazzato G: Olfactory loss in multiple sclerosis. Journal of the neurological sciences. 1999, 168 (2): 127-130. 10.1016/S0022-510X(99)00189-6.View ArticlePubMedGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.